Symbols

NUVB

Nuvation Bio·NYSE

--(--)

NUVB fundamentals

NUVB Q4 2025 Earnings

Nuvation Bio (NUVB) released its earnings on Mar 2, 2026: revenue was 41.87M (YoY +633.06%), beat estimates; EPS was -0.11 (YoY +26.67%), missed estimates.

Revenue / YoY

41.87M

+633.06%

EPS / YoY

-0.11

+26.67%

Report date

Mar 2, 2026

NUVB Earnings Call Summary for Q4,2025

IBTROZI Launch Success: 432 new patients in 2025, 6x faster growth than prior TKIs, with 50-month median response in first-line.
Financial Strength: $529M cash, $15.7M Q4 net product revenue, 25% gross to net rate, $60M Eisai upfront.
Pipeline Momentum: Safusidenib Phase III (2029 readout), DDC platform retooled, and 2026 patient starts signaling first-line expansion.

Earnings

EPS

Revenue

Revenue & Expenses

NUVB has released its 2025 Q4 earnings report, with revenue of 41.87M, reflecting a YoY change of 633.06%, and net profit of -36.59M, showing a YoY change of 25.99%. The Sankey diagram below clearly presents NUVB's revenue sources and cost distribution.

Key Indicators

Nuvation Bio (NUVB) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Nuvation Bio (NUVB)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Nuvation Bio (NUVB)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Nuvation Bio (NUVB)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown